BeOne Medicines AG
Moat Score — BeOne Medicines AG
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | BeOne holds composition-of-matter and method-of-use patents on BRUKINSA (zanubrutinib) and TEVIMBRA (tislelizumab) that run into the mid-2030s, plus a deep internally-discovered pipeline (sonrotoclax, the BTK degrader BGB-16673, multiple ADCs). This is real, FDA/NMPA-validated IP, but it sits in the single most crowded class of oncology mechanisms (BTK, PD-1), so it falls just short of a dominant, uncontested position. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | Owned large-molecule manufacturing in Hopewell, NJ and Guangzhou, China (~64,000+ liters combined) plus small-molecule capacity in Suzhou gives BeOne real unit-cost advantages over biotechs that outsource to CMOs, reflected in an 87.3% GAAP product gross margin in 2025. It is not a low-cost generic-style player, but vertical integration at this scale is a genuine, hard-to-replicate structural edge most mid-cap biotechs lack. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | BRUKINSA has maintained stable U.S. net pricing even as AstraZeneca's Calquence discounts aggressively, reflecting real clinical differentiation (superior cardiac safety vs. Imbruvica). But TEVIMBRA competes in the deeply commoditized PD-1 class against Keytruda, Opdivo, and 20+ China-originated rivals, where pricing power is limited -- so the company's pricing power is real but concentrated in one franchise, not portfolio-wide. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | BeOne's products are standard prescription therapeutics with no meaningful network effect -- a patient's or physician's choice of BRUKINSA or TEVIMBRA does not become more valuable as more patients or providers use it, unlike platform or data-network businesses. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a patient is stabilized on BRUKINSA (often an open-ended, indefinite-duration therapy for CLL/SLL) or TEVIMBRA, physicians are reluctant to switch regimens absent a clinical reason, which creates some retention. But these are still single-agent oncology drugs, not embedded platforms or multi-year infrastructure commitments, so switching costs are moderate rather than structural. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The global BTK-inhibitor and PD-1 markets are large enough to support several well-capitalized players (AbbVie/Janssen, AstraZeneca, Eli Lilly, Merck, BMS, Roche), so BeOne does not benefit from a naturally limited market the way a true niche monopolist would. Its scale advantage comes instead from having already built the expensive global trial, regulatory, and manufacturing infrastructure that a new entrant would need years and billions of dollars to replicate. |